Tamoxifen or Enclomiphene: What's the Difference

Tamoxifen and enclomiphene belong to the same class — selective estrogen receptor modulators (SERMs) — and even share a common chemical ‘ancestor’. Yet their history, metabolism, tissue action and evidence base are very different. The editorial team explains exactly what this difference consists of.

Common origin: triphenylethylenes

Both tamoxifen and clomiphene (and hence enclomiphene) are derivatives of triphenylethylene — a chemical structure actively studied in the mid-20th century as a basis for non-steroidal substances that interact with estrogen receptors. At first pharmacologists were looking for contraceptives, but they obtained compounds with unexpectedly complex behavior in different tissues.

Tamoxifen was synthesized at the British company ICI in the early 1960s. It did not work as a contraceptive, but it proved effective in hormone-dependent breast cancer. Today it is one of the most studied oncology drugs in the world, included in the WHO List of Essential Medicines.

Clomiphene appeared at about the same time and was registered for stimulating ovulation in women. It is a mixture of two isomers: enclomiphene (the trans form) and zuclomiphene (the cis form). Enclomiphene is responsible for the antiestrogenic action in the hypothalamus, whereas zuclomiphene has more estrogenic properties and a long half-life.

Enclomiphene as a separate drug was studied only in the 21st century, as an oral agent for men with secondary hypogonadism. Unlike tamoxifen, it has no oncological history and no registered indications in most countries.

Thus, a shared chemical platform does not make these substances interchangeable: each has its own clinical path, its own evidence base and its own regulatory status.

Metabolism and pharmacokinetics

Tamoxifen is largely a prodrug. In the liver, with the participation of cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, it is converted into active metabolites — 4-hydroxytamoxifen and endoxifen. It is endoxifen that has a much higher affinity for estrogen receptors than the parent molecule.

This feature has practical consequences. People with low CYP2D6 activity (genetically or because of taking some antidepressants that inhibit this enzyme) form less endoxifen. In oncology this issue is actively discussed, and the drug's official label warns about drug interactions.

The half-life of tamoxifen is about 5–7 days, and that of its metabolites even longer. A steady blood concentration is established only after several weeks of regular intake, and the substance is likewise slowly cleared after discontinuation.

Enclomiphene, by contrast, acts without obligatory metabolic activation and has a much shorter half-life, measured in hours. It quickly reaches a steady level and is quickly cleared. Against this background, tamoxifen's prolonged presence in the body is both a plus (stability) and a minus (slow disappearance of side effects).

Tissue selectivity

The main property of any SERM is the ability to be an estrogen antagonist in some tissues and a partial agonist in others. This depends on the shape of the ‘ligand–receptor’ complex, on the ratio of ERα and ERβ receptor subtypes in the tissue, and on the set of coregulator proteins.

Tamoxifen is an antagonist in breast tissue, which is what determines its antitumor action. At the same time, in bone tissue it behaves as a partial agonist and in postmenopausal women can preserve bone mineral density. In the endometrium it is also partially estrogenic, which is associated with an increased risk of endometrial hyperplasia and cancer.

For enclomiphene the most important tissue is the hypothalamus and pituitary, where it blocks estrogen feedback. There is far less data on its action in the breast, bones and endometrium than for tamoxifen, since long-term studies in large populations have not been conducted.

This is an important point for the comparison: for tamoxifen we know its behavior in almost every tissue thanks to decades of clinical observation, whereas for enclomiphene we mainly know its central action and short-term consequences.

Effect on the hormonal axis in men

In men, both drugs block estrogen feedback in the hypothalamus, as a result of which LH, FSH and testosterone rise. This effect of tamoxifen has long been known and is described in the andrological literature, although it is not a registered indication for treating male hypogonadism.

Enclomiphene was purposefully developed precisely for this effect. In the studies of Wiehle et al. (2014) and Kim et al. (2016) it raised testosterone in men with secondary hypogonadism while preserving sperm count. Tamoxifen was studied for this purpose in smaller and older studies, mainly in the context of idiopathic infertility.

A separate context for the use of tamoxifen in men is gynecomastia. Thanks to its antiestrogenic action in breast tissue, it is used off-label to treat painful gynecomastia, as well as to prevent gynecomastia in prostate cancer patients receiving antiandrogen therapy. No such use is described for enclomiphene.

So, in male endocrinology tamoxifen is a ‘more universal’ but non-specialized tool, whereas enclomiphene was created for a single task, but with a limited evidence base and without registration.

Safety profile

The safety profile of tamoxifen has been studied in detail, primarily in women. Large studies, in particular NSABP P-1 (Fisher et al., 1998), showed an increased risk of venous thromboembolism, endometrial cancer and cataract, alongside a reduced incidence of breast cancer in risk groups. The EBCTCG meta-analysis (2011) confirmed the effectiveness of adjuvant therapy in receptor-positive cancer.

In men taking tamoxifen for medical reasons, decreased libido, hot flashes, weight gain, mood swings and thromboembolic complications are reported. The risk of thrombosis is a class effect of SERMs and also applies to other members of the group.

For enclomiphene the data are limited to studies of up to a few months' duration. Headache, hot flashes, nausea have been described, as well as an increase in hematocrit in some participants, associated with a rise in testosterone. The visual disturbances characteristic of clomiphene are theoretically also possible for enclomiphene and therefore require attention.

• Common risks of the SERM class: thrombosis, visual disturbances, hot flashes, effects on lipids.
• Specific to tamoxifen: prolonged presence in the body, drug interactions via CYP2D6, and in women, the risk of endometrial cancer.
• Specific to enclomiphene: absence of long-term data and registration, risk of counterfeits.

Editorial conclusions

Tamoxifen and enclomiphene are chemical relatives with the same class of action but a different fate. Tamoxifen is a long-acting prodrug with complex tissue selectivity and decades of oncological data. Enclomiphene is a short-acting isomer of clomiphene, developed to stimulate gonadotropins in men, with a limited evidence base.

Both raise testosterone in men through a central mechanism, but neither is registered for treating male hypogonadism in Ukraine and the EU. Both are banned by WADA.

When comparing these substances, it is important to remember: the greater study of tamoxifen means not only more knowledge about benefits, but also clearly documented risks, whereas the ‘fewer known side effects’ of enclomiphene often simply means a smaller number of studies.

We also recommend reading our articles on for whom doctors consider tamoxifen or enclomiphene, on the difference between clomiphene and enclomiphene, and on raloxifene as another SERM.

References

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388.
3. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720–727.
4. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–685.
5. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
6. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205–213.
7. World Anti-Doping Agency. Prohibited List. Montreal: WADA (чинна редакція).